Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.

Abstract: The invention provides humanized antibody and other antigen-binding fragments that are specific for the newly identified dendritic cell marker BDCA-2. These agents may be used for treatment of conditions caused or mediated by dendritic cells, including but not limited to systemic lupus erythematosus (SLE). The invention includes pharmaceutical compositions that contain a means for specifically binding BDCA-2, methods of preparing therapeutic products, and their use in therapy. Methods are also provided for screening, manufacture, and use of specific antibodies that identify other dendritic cell markers.

Abstract: This invention provides a method of detecting BDCA-2 protein in a biological sample. The sample is combined with an antibody or antigen binding fragment under conditions where the antibody or fragment will bind to BDCA-2 protein in the sample to form a complex, which is detected by formation of complex with the antibody. BDCA-2 protein may be displayed on the surface of dendritic cells. Binding of the antibody may result in down-regulation of type 1 interferon production, down-regulation of Th1 immune responses, induction of intracellular Ca++ mobilization, and/or polarization of an immune response towards Th2.

Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.

Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.

Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.

Abstract: The application describes, inter alia, a method for isolating or enriching for dendritic cells from a mixture of human cells involving contacting cells in the mixture with an antibody that binds BDCA-4, or antigen-binding fragment thereof, under conditions in which the antibody or antigen-binding fragment binds BDCA-4+ dendritic cells, and separating dendritic cells bound by the antibody or antigen-binding fragment from other cells in the mixture.

Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.

Abstract: The invention provides methods of separation, enrichment and analysis of hematopoietic cell populations containing dendritic cells and subsets thereof. Compositions containing dendritic cells and methods of use of such compositions are provided.